About transcode therapeutics inc - RNAZ
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
RNAZ At a Glance
TransCode Therapeutics, Inc.
6 Liberty Square
Boston, Massachusetts 02109
| Phone | 1-857-837-3099 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -34,661,076.00 | |
| Sector | Health Technology | Employees | 12 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
RNAZ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.606 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -6.732 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
RNAZ Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,888,423.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RNAZ Liquidity
| Current Ratio | 6.291 |
| Quick Ratio | 6.291 |
| Cash Ratio | 5.098 |
RNAZ Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -40.851 |
| Return on Equity | -46.258 |
| Return on Total Capital | -22.821 |
| Return on Invested Capital | -46.258 |
RNAZ Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |